STANFORD, CA – April 24, 2024 – In a discovery poised to fundamentally reshape our understanding of cancer immunology, scientists have uncovered a critical, previously unknown function of a protein primarily recognized for its role in stimulating red blood cell production. Erythropoietin (EPO), a hormone identified nearly four decades ago, has now been revealed to play a surprising and potent role in dampening the immune system’s ability to fight cancer, acting as a stealthy antagonist in the tumor microenvironment.
This groundbreaking research demonstrates that by blocking EPO’s activity, scientists can transform immune-resistant, or "cold," liver tumors in mice into "hot" tumors, teeming with cancer-fighting immune cells. When this intervention was combined with an existing immunotherapy designed to further activate these immune cells, the results were dramatic: complete regression of established liver tumors in the majority of treated animals, which lived for the entire duration of the experiment. In stark contrast, control animals, receiving no such treatment, succumbed to the disease within weeks.
"This is a fundamental breakthrough in our understanding of how the immune system is turned off and on in cancer," exclaimed Edgar Engleman, MD, PhD, a professor of pathology and of medicine at Stanford University School of Medicine, and senior author of the research. His excitement is palpable. "I could not be more excited about this discovery, and I hope treatments that target the mechanism we uncovered will quickly move forward to human trials." The findings, which promise to unlock new therapeutic avenues for a wide range of currently untreatable cancers, are published online today in the prestigious journal Science. David Kung-Chun Chiu, PhD, a basic life research scientist, served as the lead author of the pivotal study.
Chronology of Discovery and Understanding
The journey to this pivotal discovery is a testament to scientific perseverance, the unexpected twists of biological inquiry, and the courage to challenge long-held assumptions. For decades, erythropoietin has been celebrated as a vital hormone, produced primarily by the kidneys, essential for regulating red blood cell production (erythropoiesis). Its therapeutic application in treating anemia, particularly in patients with kidney disease or those undergoing chemotherapy, has been a cornerstone of modern medicine. However, EPO’s narrative began to take a darker, more complex turn in the context of cancer patients.
The Unsettling Connection: EPO and Tumor Growth
More than a decade ago, clinical observations began to raise red flags. Studies revealed that administering exogenous EPO to anemic cancer patients – with the intent of boosting red blood cell counts and improving quality of life – inadvertently accelerated tumor growth. This troubling correlation was so pronounced that in 2007, the U.S. Food and Drug Administration (FDA) mandated a "black box" warning label on EPO-stimulating drugs, cautioning against their use in individuals with certain cancers. The scientific community was left grappling with a paradox: how could a life-sustaining hormone also fuel a life-threatening disease?
Beyond the effects of administered EPO, researchers also noted a clear and disturbing correlation between the levels of naturally occurring EPO and its receptor (EPOR) within tumors and the prognosis of cancer patients. Higher levels of both EPO and EPOR were consistently linked to poorer patient outcomes across various cancer types. Yet, the precise mechanism behind this detrimental association remained elusive.
"Those old reports showed clearly that the more EPO or EPOR there was in tumors, the worse off the patients were," Engleman reflected, recalling the perplexing data. "But the connection between EPO and cancer immunity was never made until now. In fact, it took a long time and a lot of experiments to convince us that EPO plays a fundamental role in blocking the immune response to cancer, because EPO is so well established as a red blood cell growth factor." The entrenched understanding of EPO as solely an erythropoietic agent created a significant conceptual hurdle, delaying the recognition of its broader, immunosuppressive capabilities.
Modern Investigation: Unraveling the Immune Puzzle
The breakthrough began with David Kung-Chun Chiu’s meticulous work in developing sophisticated genome-editing techniques. Chiu engineered several highly precise mouse models of liver cancer, each designed to recapitulate specific mutations, histological features, and responses to approved therapies observed in distinct subtypes of human liver cancers. These models were crucial for accurately studying tumor development and their responses to various treatments. Tumor formation was initiated either by injecting a combination of DNA encoding proteins associated with liver cancer into the animals’ tail veins or by directly implanting liver cancer cells into the animals’ livers, ensuring a robust and relevant experimental platform.
The primary focus of their initial investigations revolved around the efficacy of a common immunotherapy targeting programmed cell death protein 1 (PD-1). PD-1 is a checkpoint protein on immune cells, particularly T cells, which, when bound by ligands from cancer cells, acts as an "off switch," dampening the T cells’ activity. Anti-PD-1 therapies, such as Keytruda, have revolutionized cancer treatment for melanoma, Hodgkin’s lymphoma, and some lung cancers by blocking this interaction, thereby unleashing the T cells to attack cancer. However, a significant majority of solid tumors—including most liver, pancreas, colon, breast, and prostate cancers—remain stubbornly resistant to these breakthrough treatments. These resistant tumors are often characterized as "cold," lacking the robust immune cell infiltration necessary for immunotherapy to be effective.
Serendipitous Observation: The EPO-Hypoxia Link in Cold Tumors
In their exploration of immune resistance, the researchers observed a phenomenon strikingly similar to what is seen in human liver cancers: some combinations of genetic mutations led to the development of "cold" liver tumors that were largely ignored by the immune system. These immune-privileged tumors exhibited minimal T-cell infiltration and, consequently, showed no response to anti-PD-1 treatment. In stark contrast, other genetic mutations resulted in "hot," or "inflamed," tumors, replete with T cells and highly sensitive to anti-PD-1, which successfully triggered an immune attack on the cancer.
It was during this comparative analysis that an unexpected and critical observation emerged: the cold tumors consistently displayed elevated levels of EPO compared to their hot counterparts. The underlying cause of this EPO surge appeared to be the oxygen-poor microenvironment—a condition known as hypoxia—prevalent within these cold, rapidly growing tumors. Hypoxia is a common feature of many solid tumors, driven by chaotic and inefficient blood vessel formation that fails to meet the high metabolic demands of proliferating cancer cells. In an attempt to compensate for the low oxygen, cancer cells in hypoxic conditions induce the production of various proteins, which, in turn, ramp up the production of EPO, theoretically to stimulate more red blood cell formation and improve oxygen delivery.
"Hypoxia in tumors has been studied for decades," Engleman noted, underscoring the long-standing focus on this aspect of tumor biology. "It just didn’t dawn on anyone, including me, that EPO could be doing anything in this context other than serving as a red blood cell growth factor." This pivotal insight marked the turning point, prompting the research team to investigate EPO’s role beyond its established erythropoietic function.
Supporting Data and Experimental Details
To validate their hypothesis, the researchers delved into existing clinical databases, confirming that elevated EPO levels are indeed correlated with poorer survival rates in human patients across a spectrum of cancers, including those of the liver, kidney, breast, colon, and skin. Armed with this epidemiological support, they proceeded with a series of rigorous experimental manipulations in their mouse models, designed to directly test EPO’s influence on tumor immunity.
Manipulating EPO Levels: A Dramatic Reversal
The first set of experiments involved tinkering with the tumor cells’ ability to produce EPO. What happened next was nothing short of astonishing. Mutations that had previously led to the development of immune-resistant, "cold" tumors now resulted in "hot" tumors when those tumor cells were genetically modified to be unable to make EPO. This demonstrated a direct causal link: the absence of tumor-derived EPO transformed the immune landscape of the tumor. Conversely, "hot" tumors, which had previously been successfully eradicated by the immune system, thrived and grew aggressively when they were engineered to produce elevated levels of EPO. These elegant experiments provided irrefutable evidence that tumor-derived EPO actively dictates the immune status of the tumor, shifting it from an immune-responsive state to an immune-evasive one.
Elucidating the Mechanism: EPO-Macrophage Crosstalk
The next critical step was to unravel the precise molecular and cellular mechanism by which EPO exerted its immunosuppressive effects. Through exhaustive research, the team discovered a crucial signaling pathway: in cold tumors, the tumor cells themselves produce and secrete EPO. This secreted EPO then binds to specific receptors (EPOR) located on the surface of immune cells known as macrophages, which are abundant in the tumor microenvironment.
Upon binding to EPO, these macrophages undergo a profound transformation. They switch from a potentially anti-tumorigenic role to an immunosuppressive phenotype. In their newly reprogrammed state, these EPO-activated macrophages actively "shoo away" cancer-killing T cells, preventing them from infiltrating the tumor. Furthermore, they actively tamp down the activity of any T cells that manage to breach the tumor’s defenses, effectively creating an immune exclusion zone and an immunosuppressive milieu. This EPO-moderated crosstalk between tumor cells and macrophages emerged as the central lynchpin in the mechanism of immune evasion.
The Power of Combination Therapy: A Glimpse into Future Treatments
The importance of this EPO-macrophage axis became starkly clear when the researchers investigated the combinatorial effect of simultaneously blocking the EPO signaling pathway and the anti-PD-1 pathway. These experiments were designed to mimic a potential therapeutic strategy: disarming EPO’s immunosuppressive influence while simultaneously boosting the T cells’ inherent anti-cancer activity.
The results were compelling and offered immense hope. In control groups, mice with cold liver tumors treated with either a placebo or anti-PD-1 alone showed no significant survival benefit, with none living more than eight weeks after tumor induction. However, in mice where the macrophages were genetically modified to be unable to express the EPO receptor, thereby disrupting the EPO signaling pathway, 40% of the animals lived for 18 weeks after tumor induction, at which point the experiment was terminated. The most remarkable outcome was observed when anti-PD-1 treatment was administered to mice lacking the EPO receptor on their macrophages: all animals in this combination therapy group lived for the entire duration of the experiment, demonstrating a complete and sustained regression of their tumors.
"It’s simple," Engleman summarized, highlighting the profound yet elegant nature of the discovery. "If you remove this EPO signaling, either by lowering the hormone levels or by blocking the receptors on the macrophages, you don’t just get a reduction in tumor growth, you get tumor regression along with sensitivity to anti-PD-1 treatment." This synergistic effect points towards a powerful new therapeutic strategy for overcoming resistance to existing immunotherapies.
Official Responses and Broader Implications
The findings from this Science publication carry immense weight, reverberating through both the scientific community and the realm of clinical oncology. The most immediate and striking implication is the reinterpretation of the FDA’s 2007 black box warning for EPO use in cancer patients. What was once understood as a vague acceleration of tumor growth can now be precisely attributed to EPO’s newly identified role in actively suppressing the anti-tumor immune response. This provides a mechanistic explanation for decades of puzzling clinical observations, validating the concerns that led to the original warning.
Expanding the Therapeutic Horizon
This discovery holds particular promise for patients suffering from "cold" tumors – cancers that currently resist the transformative power of PD-1 inhibitors and other immunotherapies. Liver, pancreatic, colorectal, breast, and prostate cancers, which collectively account for a significant burden of cancer mortality, are often characterized by their immune-resistant nature. By understanding how EPO orchestrates immune dampening, researchers can now envision strategies to "warm up" these cold tumors, making them susceptible to existing and future immunotherapeutic agents.
The research suggests a paradigm shift in how we approach the tumor microenvironment. Instead of viewing hypoxia-induced EPO production merely as a compensatory mechanism for oxygen deprivation, it must now be recognized as a deliberate strategy employed by tumors to evade immune surveillance. This opens up entirely new avenues for therapeutic intervention, potentially transforming patient outcomes for a broad spectrum of currently intractable cancers.
Future Therapeutic Strategies: Navigating Challenges
Engleman and his colleagues are already actively designing new treatment strategies that specifically target EPO signaling in human cancers. Several approaches are being considered:
- Direct EPO Inhibition: One strategy involves non-specifically targeting the EPO protein itself, either by reducing its production or neutralizing its activity. While potentially highly effective, this approach carries a known side effect: anemia, as EPO is crucial for red blood cell formation. Engleman speculates that for an effective cancer therapy, this might be an acceptable trade-off, particularly in late-stage or aggressive cancers. However, careful management and patient selection would be paramount.
- Selective EPOR Blocking on Macrophages: A more refined approach involves selectively blocking the EPO receptors specifically on the surface of macrophages within the tumor microenvironment. This strategy aims to disrupt the immunosuppressive cascade without interfering with EPO’s systemic role in red blood cell production, potentially mitigating the risk of anemia and other systemic side effects. Such targeted therapies would represent a significant advancement in precision oncology.
- Combination Therapies: The most compelling immediate application lies in combining EPO-targeting agents with existing immunotherapies, particularly anti-PD-1/PD-L1 antibodies. The synergistic effects observed in the mouse models—leading to complete tumor regression—underscore the potential of such a combinatorial approach to overcome immune resistance and dramatically improve patient responses.
Looking Ahead: Challenges and Opportunities
The journey from a preclinical discovery in mouse models to a validated human therapy is often long and arduous, yet the foundational strength of this research provides immense optimism. The next critical step is to translate these findings into human clinical trials. This will involve developing safe and effective drugs that can either reduce tumor-derived EPO or selectively block its receptor on macrophages.
While the current study focused on liver cancer, the underlying mechanisms—tumor hypoxia, EPO production, macrophage reprogramming, and T-cell exclusion—are common features in many solid tumors. This suggests that the implications of this discovery are likely to extend far beyond liver cancer, potentially offering a therapeutic strategy applicable to a wide array of cancers that currently defy effective immunotherapy.
This research also serves as a powerful reminder of the iterative nature of scientific discovery. Long-held beliefs and established physiological roles of proteins can sometimes mask deeper, more complex functions. The ability of the research team to revisit a well-known protein with fresh eyes, driven by unexpected observations, allowed them to uncover a hidden layer of cancer biology.
The study was funded by significant grants from the National Institutes of Health (R01CA262361, P01CA244114, U54CA2745115, and P01HL149626), underscoring the collaborative nature of advanced biomedical research. Researchers from the New York Blood Center and the pharmaceutical company ImmunEdge Inc. also contributed to the effort. It is important to note the affiliations and potential conflicts of interest: David Kung-Chun Chiu is a cofounder of ImmunEdge Inc., and Edgar Engleman is a founder, shareholder, and board member of ImmunEdge Inc. Both Chiu and Engleman are Stanford-affiliated inventors of a patent application (PCT/US2023/063997) entitled "EPO receptor agonists and antagonists," reflecting the direct translational potential of their groundbreaking work.
"I continue to be amazed by this finding," Engleman concluded, reflecting on the magnitude of their discovery. "Not every tumor is going to respond in the same way, but I’m very optimistic that this discovery will lead to powerful new cancer therapies." Indeed, by peeling back another layer of cancer’s complex immune evasion strategies, this research offers a beacon of hope for countless patients, promising a future where "cold" tumors can finally be turned "hot," and the body’s own immune system can be fully unleashed to fight disease.
About the Author
